

## Fan Xing Xing



**Position** Assistant Professor

**Faculty** State Key Laboratory of Quality  
Research in Chinese Medicines

**Email address** xxfan@must.edu.mo

**Office** H836

**Mailing  
address** Room 836, Block H, Macau  
University of Science and  
Technology, Avenida Wai Long,  
Taipa, Macau

### *Teaching and Research Areas*

Molecular pharmacology, Cancer immunotherapy

### *Academic Qualifications*

2011-2014 PhD/Chinese Medicines/Macau University of Science and  
Technology

2007-2010 MPhil / Pathogen biology / TianJin Medical University

2002-2007 BSC / Clinical Medicine / TianJin Medical University

### *Experiences*

2014-2017 Postdoctoral training/ SKL of quality research in Chinese  
Medicines / Macau University of Science and Technology

### *Representative Publications*

*Journal Articles:* (\*corresponding author(s); #contribution equally)

1. **Fan XX**<sup>#</sup>, Pan HD<sup>#</sup>, Li Y, Guo RJ, Leung EL<sup>\*</sup>, Liu L<sup>\*</sup>. Novel therapeutic strategy for cancer and autoimmune conditions: Modulating cell metabolism and redox capacity. *Pharmacol Ther.* 2018 Jun 25. pii: S0163-7258(18)30112-8.
2. Li RZ<sup>#</sup>, **Fan XX**<sup>#</sup>, Duan FG, Jiang ZB, Pan HD<sup>1</sup>, Luo LX, Zhou YL, Li Y, Yao YJ, Yao XJ, Leung EL<sup>\*</sup>, Liu L<sup>\*</sup> (7258()3(18)30)3(1)40(12)]ng T EMCn-US

survival in lung adenocarcinoma. *Oncotarget*. 2016 Jun 28; 7 (26): 39970-39979.

9. Wang MF, Li RZ, Li Y, Cheng XQ, Yang J, Chen W, **Fan XX**, Pan HD, Yao XJ, Ren T, Qian X, Liu L, Leung EL\*, Tang YJ\*. Clinical statistics analysis on the characteristics of pneumoconiosis of Chinese miner population. *J Thorac Dis*. 2016 Aug;8(8):2203-11.

10. Jiang JB<sup>#</sup>, Huang J<sup>#</sup>, Xie C, Li X, Liu L, He J, Pan H, Huang L, **Fan XX**, Yao XJ, Xie Y, Li N, Liu L, He JX\* & Leung EL\*. Combined use of PI3k and MEK inhibitors synergistically inhibits lung cancer with EGFR and KRAS mutation. *Oncology Reports*. 2016 Jul; 36(1):365-75.

11. Xu SW, Law BY, Mok SW, Leung EL, **Fan XX**, Coghi PS, Zeng W, Leung CH, Ma DL, Liu L, Wong VK\*. Autophagic degradation of epidermal growth factor receptor in gefitinib-resistant lung cancer by celastrol. *Int J Oncol*. 2016 Oct; 49(4):1576-88.

12. Zhang YZ<sup>#</sup>, Chen X<sup>#</sup>, **Fan XX**, He JX, Huang J, Xiao DK, Zhou YL, Zheng SY, Xu JH, Yao XJ, Liu L\* & Leung EL\*. Compound library screening identified cardiac glycoside digitoxin as effective growth inhibitor of gefitinib-resistant non-small cell lung cancer via downregulation of  $\alpha$ -tubulin and inhibition of microtubule formation. *Molecules*. 2016 Mar 18; 21(3).

13. **Fan XX**, Yao XJ, Xu SW, Wong VKW, He JX, Ding J, Xue WW, Mujtaba T, Michelangeli F, Huang M, Huang J, Xiao DK, Jiang ZB, Zhou YL, Kam R.K., Liu L\*, Leung EL\* -Trans-tetramethoxystilbene, a new analogue of resveratrol, inhibits gefitinib-resistant non-small cell lung cancer via selectively elevating intracellular calcium level. *Sci Reports*. 2015 Nov 6; 5:16348.

14. Leung EL, **Fan XX**, Wong MP, Jiang ZH, Liu ZQ, Yao XJ, Lu LL, Zhou YL, Yau LF, Tin PC, Liu L\*. Targeting tyrosine kinase inhibitor resistant non-small-cell lung cancer by inducing EGFR degradation via methionine 790 oxidation. *Antioxid Redox Signal*. 2016 Feb 10;24(5):263-79.

15. Yuan ZW, Leung EL, **Fan XX**, Ma WZ, Liu L, Xie Y\*. Quantitative evaluation of berberine subcellular distribution and cellular accumulation in non-small cell lung cancer cells by UPLC-MS/MS. *Talanta*. 2015 Nov 1; 144: 20-8.

16. **Fan XX**, Li N, Wu JL, Zhou YL, He JX, Liu L and Leung EL\*. Celastrol Induces Apoptosis in Gefitinib-Resistant Non-Small Cell Lung Cancer Cells via Caspases-Dependent Pathways and Hsp90 Client Protein Degradation. *Molecules*. 2014 Mar 21; 19(3):3508-22.